Neurogene (NASDAQ:NGNE) Research Coverage Started at BMO Capital Markets

BMO Capital Markets initiated coverage on shares of Neurogene (NASDAQ:NGNE) in a report issued on Thursday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $65.00 target price on the stock.

Other equities analysts also recently issued research reports about the stock. Robert W. Baird assumed coverage on shares of Neurogene in a report on Tuesday, June 11th. They issued an outperform rating and a $54.00 price objective on the stock. HC Wainwright reissued a buy rating and issued a $51.00 price objective on shares of Neurogene in a report on Thursday, June 20th. Baird R W raised shares of Neurogene to a strong-buy rating in a report on Tuesday, June 11th. SVB Leerink assumed coverage on shares of Neurogene in a report on Monday, April 29th. They issued an outperform rating and a $46.00 price objective on the stock. Finally, Leerink Partnrs reissued an outperform rating on shares of Neurogene in a report on Monday, April 29th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Neurogene presently has an average rating of Buy and a consensus target price of $51.33.

Neurogene Trading Up 4.5 %

Shares of NASDAQ NGNE opened at $36.39 on Thursday. The company’s 50-day moving average is $33.95. Neurogene has a 52-week low of $12.20 and a 52-week high of $53.00.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings results on Friday, May 10th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.03. On average, equities research analysts forecast that Neurogene will post -4.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neurogene

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in Neurogene during the 1st quarter worth approximately $120,000. Privium Fund Management UK Ltd bought a new stake in shares of Neurogene during the first quarter valued at approximately $274,000. BML Capital Management LLC bought a new stake in shares of Neurogene during the fourth quarter valued at approximately $478,000. Avidity Partners Management LP bought a new stake in shares of Neurogene during the fourth quarter valued at approximately $9,036,000. Finally, Great Point Partners LLC bought a new stake in shares of Neurogene during the fourth quarter valued at approximately $19,268,000. Institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.